IP Library Granted Patent US 9,999,675
Granted Patent B2
US 9,999,675 · App. 15/357,496 · Granted Jun 19, 2018

Composition and method for delivery of hydrophobic active agents

Inventors: Joseph Ventura (Elk Grove, CA); Shannon Wadman (Minneapolis, MN); Joram Slager (St. Louis Park, MN); Joseph Schmidt McGonigle (Minneapolis, MN); Robert W. Hergenrother (Vestavia, AL)
Assignee: Surmodics, Inc.
A61K47/34A61K9/08A61K31/337A61L27/18A61L27/54A61K9/0019A61L2300/416A61L2300/63A61L2400/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,999,675
App. No.
15/357,496
Granted
Jun 19, 2018
Kind
B2
Abstract

Disclosed herein is a delivery composition for administering a hydrophobic active agent. In one embodiment, a delivery composition for local administration of a hydrophobic active agent to a tissue or organ of a patient is disclosed. In one embodiment, the delivery composition includes a cationic delivery agent, a therapeutically effective amount of a hydrophobic active agent and a pharmaceutically acceptable aqueous carrier. In one embodiment, the cationic delivery agent includes polyethyleneimine (PEI). In a more specific embodiment, the cationic delivery agent includes branched PEI. Methods of making the delivery composition, as well as kits and methods of use are also disclosed.

Claims (24)

1. A kit comprising:

a delivery composition in a liquid form comprising:

(A) a hydrophobic active agent; and

(B) a cationic delivery agent selected from the group consisting of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), polyamidoamine dendrimers (PAMAM), polypropylenimine, and polyethyleneimine (PEI) homopolymer;

wherein the hydrophobic active agent interfaces with the cationic delivery agent; and

wherein the cationic delivery agent is effective to improve adhesion of the hydrophobic active agent to surfaces.

2. The kit according to claim 1 , comprising solid hydrophobic active agent.

3. The kit according to claim 1 , comprising hydrophobic active agent in an aqueous solution.

4. The kit according to claim 2 , comprising amorphous hydrophobic active agent.

5. The kit according to claim 2 , comprising crystalline hydrophobic active agent.

6. The kit according to claim 1 , comprising amorphous cationic delivery agent.

7. The kit according to claim 1 , comprising crystalline cationic delivery agent.

8. The kit according to claim 1 , comprising cationic delivery agent in an aqueous solution.

9. The kit according to claim 1 , further comprising a pharmaceutically acceptable aqueous carrier.

10. The kit according to claim 1 , further comprising instructions for use.

11. The kit according to claim 1 , comprising:

a suspension comprising the hydrophobic active agent; and

instructions to combine the cationic delivery agent with the suspension of hydrophobic active agent.

12. The kit according to claim 1 , comprising:

a mixture of solid hydrophobic active agent and cationic delivery agent having a ratio of hydrophobic active agent:cationic delivery agent of less than about 1:5 and instructions to reconstitute the mixture with a pharmaceutically acceptable aqueous carrier.

13. The kit according to claim 1 , comprising:

a suspension comprising the solid hydrophobic active agent and cationic delivery agent in a pharmaceutically acceptable aqueous carrier, wherein the suspension has a pH of between about 5 and about 9.

14. The kit according to claim 1 , wherein the hydrophobic active agent is selected from an antiproliferative, analgesic, anti-inflammatory, anti-arrhythmic, anti-bacterial, anti-coagulant, anti-hypertensive, anti-muscarinic, anti-neoplastic, beta-blocker, cardiac inotropic agent, corticosteroids, lipid regulating agents, anti-anginal agents, and combinations thereof.

15. The kit according to claim 1 , wherein the hydrophobic active agent comprises an antiproliferative selected from paclitaxel, sirolimus (rapamycin), everolimus, biolimus A9, zotarolimus, tacrolimus, and pimecrolimus and mixtures thereof.

Assignments (5)
SECURITY INTEREST Recorded Jan 21, 2026
From: SURMODICS COATINGS, LLC
To: BANK OF MONTREAL, AS COLLATERAL AGENT
Reel/Frame 074461/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2025
From: SURMODICS, INC.
To: SURMODICS COATINGS, LLC
Reel/Frame 073928/0178 →
RELEASE OF SECURITY INTEREST Recorded Nov 24, 2025
From: MIDCAP FUNDING IV TRUST
To: SURMODICS, INC.; SURMODICS SHARED SERVICES, LLC; SURMODICS HOLDINGS, LLC; SURMODICS COATINGS, LLC; SURMODICS MD, LLC; SURMODICS COATINGS MFG, LLC; SURMODICS IVD, INC.; SURMODICS MD OPERATIONS, LLC; NORMEDIX, INC.
Reel/Frame 073690/0186 →
SECURITY INTEREST Recorded Aug 23, 2024
From: SURMODICS, INC.; SURMODICS SHARED SERVICES, LLC; SURMODICS HOLDINGS, LLC; SURMODICS COATINGS, LLC; SURMODICS MD, LLC; SURMODICS COATINGS MFG, LLC; SURMODICS IVD, INC.; SURMODICS MD OPERATIONS, LLC; NORMEDIX, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 068762/0423 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2016
From: VENTURA, JOSEPH; WADMAN, SHANNON; SLAGER, JORAM; MCGONIGLE, JOSEPH SCHMIDT; HERGENROTHER, ROBERT W.
To: SURMODICS, INC.
Reel/Frame 040399/0312 →
Continuity (4)
Division 14072520 · Nov 5, 2013
Provisional Application 61740713 · Dec 21, 2012
Provisional Application 61722735 · Nov 5, 2012
Related Publication 20170072057A1 · Mar 16, 2017